ANI Pharmaceuticals Inc. (ANIP)
68.38
1.21 (1.80%)
At close: Mar 27, 2025, 3:59 PM
73.74
7.83%
After-hours: Mar 27, 2025, 06:29 PM EDT
ANI Pharmaceuticals Inc. Revenue Breakdown
| Quarter | Sep 30, 2024 | Mar 31, 2020 | Sep 30, 2019 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unapproved Products Revenue | 5.5M | 4.4M | 4.7M | 6.7M | 7.9M | 6.7M | 6.2M | 7.7M | 5K | 100K | 100K | 10.5M | 100K | 100K | 100K | 100K | 100K | 3.8M | 100K | 9.98K | 134.75K | 105.6K |
| Unapproved Products Revenue Growth | +25.00% | -6.38% | -29.85% | -15.19% | +17.91% | +8.06% | -19.48% | +153900.00% | -95.00% | 0.00% | -99.05% | +10400.00% | 0.00% | 0.00% | 0.00% | 0.00% | -97.37% | +3700.00% | +901.80% | -92.59% | +27.60% | n/a |
Revenue by Geography
| Quarter | Dec 31, 2023 |
|---|---|
| Canada Revenue | 565K |
| Canada Revenue Growth | n/a |
| United States Revenue | 486.25M |
| United States Revenue Growth | n/a |
Operating Expense Breakdown
| Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 79.08M | 52.82M | 48.02M | 44.46M | 42.01M | 38.76M | 36.47M | 33.19M | 30.08M | 31.96M | 28.82M | 30.71M | 17.18M | 18.82M | 17.59M | 14.37M | 15.72M | 21.21M | 13.68M | 14.01M | 14.36M | 14.19M | 13.28M | 13.38M | 11.77M | 9.96M | 8.96M | 8.88M | 8.02M | 7.38M | 7.29M | 7.37M | 6.93M | 7.63M | 5.9M | 5.46M | 5.4M | 5.55M | 4.75M |
| Selling, General, and Administrative Revenue Growth | +49.70% | +10.00% | +8.00% | +5.84% | +8.38% | +6.28% | +9.88% | +10.33% | -5.87% | +10.90% | -6.15% | +78.72% | -8.71% | +7.01% | +22.43% | -8.65% | -25.87% | +55.03% | -2.36% | -2.39% | +1.19% | +6.81% | -0.69% | +13.65% | +18.14% | +11.23% | +0.80% | +10.76% | +8.70% | +1.19% | -1.03% | +6.37% | -9.18% | +29.20% | +8.23% | +1.04% | -2.74% | +16.84% | n/a |
| Research and Development Revenue | 10.13M | 7.3M | 10.51M | 9.87M | 11.12M | 7.37M | 5.92M | 5.22M | 7.66M | 4.17M | 5.27M | 3.14M | 2.46M | 2.81M | 2.97M | 3.68M | 2.94M | 3.04M | 6.34M | 4.68M | 4.98M | 5.77M | 4.37M | 3.48M | 4.67M | 5.14M | 2.1M | 2.65M | 2.63M | 2.17M | 1.62M | 135K | 1.04M | 764K | 966K | 661K | 815K | 995K | 403K |
| Research and Development Revenue Growth | +38.82% | -30.59% | +6.53% | -11.28% | +50.81% | +24.48% | +13.44% | -31.80% | +83.84% | -21.03% | +67.96% | +27.85% | -12.44% | -5.49% | -19.41% | +25.31% | -3.16% | -52.16% | +35.61% | -6.10% | -13.70% | +32.01% | +25.59% | -25.39% | -9.15% | +144.39% | -20.71% | +0.65% | +21.55% | +33.93% | +1098.52% | -87.03% | +36.26% | -20.91% | +46.14% | -18.90% | -18.09% | +146.90% | n/a |